Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant...

Prof Thomas Flaig - University of Colorado Denver, Denver, USA

SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )

Genetic testing and PARP inhibitors in metastatic prostate cancer

Dr Neal Shore and Dr Joaquin Mateo

Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi

Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )

Prostate cancer updates: TITAN and ENZAMET

Prof Ian Davis and Prof Axel Merseburger

Prostate cancer updates: TITAN and ENZAMET ( Prof Ian Davis and Prof Axel Merseburger )

Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019

Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger

Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019 ( Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger )

Metastatic bladder cancer: Current practice and latest data from ASCO 2019

Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones

Metastatic bladder cancer: Current practice and latest data from ASCO 2019 ( Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones )

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana

Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

Novel therapies in the treatment of bladder cancer

Dr Petros Grivas and Dr Andrea Necchi

Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer...

Prof Arnaud Mejean - Paris Descartes University, Paris, France

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )

Enzalutamide as treatment for men with mHSPC who have received testosterone...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer